Stephanie O’brien
Morningside Ventures Extensive Director experience of novel science companies
Morningside Ventures Extensive Director experience of novel science companies
Expert on epidemiology, outbreaks and protective immunity
Former Director of KU Macromolecule and Vaccine Stabilization Center. MIT & MERCK head of formulation
Oxford Vaccine Group, Joint Committee on Vaccination and Immunisation, WHO SAGE member
Commercial Director, Executive leader 13 Biopharmaceutical Product launches Merck, Sanofi, MSD
27 years bioprocess development & commercialization at Merck.